Factive
Product Images NDC 44004-321

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Factive (NDC 44004-321). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Vansen Pharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Factive 5 Count Label (Favtive 5 Count Label)

Factive 5 Count Label (Favtive 5 Count Label)
This is a medication package for Factive, containing 5 tablets of 320mg gemifloxacin mesylate. It is recommended to store the package at 25°C and protect it from light. The medication is indicated to be taken once daily. It is manufactured by Vansen Pharma Inc., and the NDC code is 44004-321-05. The package includes instructions to take one tablet per day and indicates that each tablet contains a dosage equivalent to 220mg of gemifloxacin. *
FDA Label Image

Factive 7 Count Label (Favtive 7 Count Label)

Factive 7 Count Label (Favtive 7 Count Label)
This is a description of a medication package containing tablets used for a 7-day therapy. The tablets are stored in a child-resistant package and have NDC code 44004-321-07. The medication should be protected from light and kept at a temperature of 25°C (77°F), with excursions allowed between 15°C-30°C (53°F-86°F). The tablets contain gemifloxacin mesylate and are manufactured by Vansen Pharma Inc. There is no information on the purpose of the medication.*
FDA Label Image

Table 11 (Table 11)

Table 11 (Table 11)
This text appears to be a table showing the results of a clinical and bacteriological screening for different types of antibiotic resistance. The table includes the percentage of success in identifying resistance to Penicillin, 4th generation cephalosporin, Vancomycin, Trimehoprmisulfameforazole and Tetracycline. The bacteriological screening appears to have been more successful in identifying resistant strains, with higher percentages of success across all categories.*
FDA Label Image

Table 12 (Table 12)

Table 12 (Table 12)
The text shows a table with different rates of cure for clinical bacteriological eradication with S-pneumonize and MORSP, according to the level of resistance to different antimicrobials. The table shows that the cure rate decreases as the level of resistance to antimicrobials increases. The data suggests that the cure rate for badremia with MDRSP is 100%.*
FDA Label Image

Table 2 (Table 2)

Table 2 (Table 2)
FDA Label Image

Table 3 (Table 3)

Table 3 (Table 3)
The text contains numerical data related to the number of patients and the percentage of female and male patients in different age groups undergoing different treatments. However, some numbers are not clear due to the use of incorrect characters obtained by the .*
FDA Label Image

Table 4 (Table 4)

Table 4 (Table 4)
This is a document outlining the recommended doses and durations of treatment for bacterial infections such as chronic bronchitis and pneumonia caused by specific bacteria. For acute bacterial exacerbation of chronic bronchitis and community-acquired pneumonia of mild to moderate severity caused by S. pneumoniae, H. influenzae, M. pneumoniae, or C. pneumoniae, the recommended dose is one 320 mg tablet per day for five days. If the pneumonia is caused by MDRSP, K. pneumoniae, or M. catarrhalis, the recommended dose is one 320 mg tablet per day for seven days. MDRSP refers to multi-drug resistant Streptococcal pneumoniae infections.*
FDA Label Image

Table 6 (Table 6)

Table 6 (Table 6)
FDA Label Image

Table 7 (Table 7)

Table 7 (Table 7)
FDA Label Image

Table 8 (Table 8)

Table 8 (Table 8)
This is a table showing the percentage of different pathogens present in a sample. The pathogens listed include Shepococeus preuTonze, Hyeoplasia preumoniae, Haemophilus influenzae, and Chlamytia preumoniae. The numbers in the table represent the number of samples containing each pathogen, with the percentage of samples containing each pathogen listed in the next column.*
FDA Label Image

Table 9 (Table 9)

Table 9 (Table 9)
Success rates and treatment differences for three studies evaluating the efficacy of FACTIVE 320 mg in treating bacterial infections are shown in the table. The drug regimen involved 320 mg taken orally for different durations ranging from 7 to 17 days, and the success rate was determined by the percentage of patients with successful outcomes. Study 061 showed the highest success rate of 91.7%, whereas study 267 showed the lowest success rate of 89.8%. The treatment difference was calculated by subtracting the success rate of the control group from that of the FACTIVE-treated group.*
FDA Label Image

Gemifloxacin Mesylate (Factive 1)

Gemifloxacin Mesylate (Factive 1)
FDA Label Image

Creatinine Clearance Formula (Factive 2)

Creatinine Clearance Formula (Factive 2)
This text is a formula for calculating the creatinine clearance for men based on their age, weight, and serum creatinine levels.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.